標的の活性化によって活性化されるバイオオルトゴン PROTAC プロドラッグ
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究は,がん細胞のキメラを標的としたタンパク質分解を選択的に活性化し,毒性を最小限に抑え,標的タンパク質の分解を可能にする新しい前薬戦略である,クリックリリースPROTACs (crPROTACs) を導入します.
科学分野
- 生物化学
- 分子生物学
- 化学生物学
背景
- タンパク質分解を標的とするキメラ (PROTAC) は治療的可能性を秘めているが,標的外タンパク質の分解による毒性の懸念に直面している.
- 副作用を最小限に抑えるには,PROTACの活性を正確に制御するための戦略を策定することが重要です.
- PROTACの選択性を高めるために,がんバイオマーカー活性化プロドラッグが研究されている.
研究 の 目的
- 癌細胞の標的型PROTAC活性化のためのバイオオートホーゴナル,オンデマンドプロドラッグ戦略を開発する.
- 癌細胞で選択的にタンパク質を分解するシステムを 作り出すこと
- クリックリリースのPROTAC (crPROTAC) の効果を調査する.
主な方法
- 設計された無活性PROTAC前薬 (TCO-ARV-771,TCO-DT2216) は,トランスサイクロクテン (TCO) をVHL E3ユビキチンリガゼリガンドに結合させる.
- テトラジン (Tz) 改変RGDペプチド (c(RGDyK) -Tz) を使用し,前薬活性化のためにがん細胞のインテグリンαvβ3バイオマーカーを標的とした.
- 選択的なPROTAC活性化と,その後のタンパク質分解のためのバイオオートゴーナル・クリック・リリースのメカニズムを使用した.
主要な成果
- PROTAC前薬は,インテグリン αv3依存の方法で選択的に活性化されました.
- 活性化されたPROTACは,特にがん細胞内の関心のあるタンパク質 (POI) を効果的に分解しました.
- ガン細胞と非ガン細胞の異なるPOIの標的分解が実証された.
結論
- crPROTAC戦略は,PROTACの標的の活性化を可能にし,がん細胞の選択的なタンパク質分解につながります.
- このバイオオートホグナルアプローチは,ユビキチン-プロテアソーム経路を通じて癌細胞死を誘発する潜在的な方法を提供します.
- crPROTACsは,標的外効果を減らす標的型がん治療のための有望なアビオティック戦略です.
関連する概念動画
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....

